ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Operating Income
ABL Bio Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Operating Income
-₩59.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Operating Income
₩314B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
0%
|
CAGR 10-Years
8%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Operating Income
-₩138.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Operating Income
₩156.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Operating Income
₩109.6B
|
CAGR 3-Years
30%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Operating Income
-₩5.7B
|
CAGR 3-Years
39%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Operating Income?
Operating Income
-59.4B
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's Operating Income amounts to -59.4B KRW.
What is ABL Bio Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-8%
Over the last year, the Operating Income growth was -2 169%. The average annual Operating Income growth rates for ABL Bio Inc have been -4% over the past three years , -8% over the past five years .
You don't have any saved screeners yet